table of content
1 Study Coverage
1.1 Noninvasive Cancer Diagnostics Revenue in Noninvasive Cancer Diagnostics Business (2017-2022) & (US$ Million) Introduction
1.2 Global Noninvasive Cancer Diagnostics Outlook 2017 VS 2022 VS 2028
1.2.1 Global Noninvasive Cancer Diagnostics Market Size for the Year 2017-2028
1.2.2 Global Noninvasive Cancer Diagnostics Market Size for the Year 2017-2028
1.3 Noninvasive Cancer Diagnostics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Noninvasive Cancer Diagnostics in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Noninvasive Cancer Diagnostics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Noninvasive Cancer Diagnostics Market Dynamics
1.4.1 Noninvasive Cancer Diagnostics Industry Trends
1.4.2 Noninvasive Cancer Diagnostics Market Drivers
1.4.3 Noninvasive Cancer Diagnostics Market Challenges
1.4.4 Noninvasive Cancer Diagnostics Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Noninvasive Cancer Diagnostics by Type
2.1 Noninvasive Cancer Diagnostics Market Segment by Type
2.1.1 Clinical Chemistry
2.1.2 Immunochemistry/Immunoassay
2.1.3 Molecular Diagnostics
2.1.4 Others
2.2 Global Noninvasive Cancer Diagnostics Market Size by Type (2017, 2022 & 2028)
2.3 Global Noninvasive Cancer Diagnostics Market Size by Type (2017-2028)
2.4 United States Noninvasive Cancer Diagnostics Market Size by Type (2017, 2022 & 2028)
2.5 United States Noninvasive Cancer Diagnostics Market Size by Type (2017-2028)
3 Noninvasive Cancer Diagnostics by Application
3.1 Noninvasive Cancer Diagnostics Market Segment by Application
3.1.1 Solid Tumors
3.1.2 Blood Cancer
3.1.3 Lung Cancer
3.1.4 Breast Cancer
3.1.5 Others
3.2 Global Noninvasive Cancer Diagnostics Market Size by Application (2017, 2022 & 2028)
3.3 Global Noninvasive Cancer Diagnostics Market Size by Application (2017-2028)
3.4 United States Noninvasive Cancer Diagnostics Market Size by Application (2017, 2022 & 2028)
3.5 United States Noninvasive Cancer Diagnostics Market Size by Application (2017-2028)
4 Global Noninvasive Cancer Diagnostics Competitor Landscape by Company
4.1 Global Noninvasive Cancer Diagnostics Market Size by Company
4.1.1 Top Global Noninvasive Cancer Diagnostics Companies Ranked by Revenue (2021)
4.1.2 Global Noninvasive Cancer Diagnostics Revenue by Player (2017-2022)
4.2 Global Noninvasive Cancer Diagnostics Concentration Ratio (CR)
4.2.1 Noninvasive Cancer Diagnostics Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Noninvasive Cancer Diagnostics in 2021
4.2.3 Global Noninvasive Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Noninvasive Cancer Diagnostics Headquarters, Revenue in Noninvasive Cancer Diagnostics Business (2017-2022) & (US$ Million) Type
4.3.1 Global Noninvasive Cancer Diagnostics Headquarters and Area Served
4.3.2 Global Noninvasive Cancer Diagnostics Companies Revenue in Noninvasive Cancer Diagnostics Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Noninvasive Cancer Diagnostics Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Noninvasive Cancer Diagnostics Market Size by Company
4.5.1 Top Noninvasive Cancer Diagnostics Players in United States, Ranked by Revenue (2021)
4.5.2 United States Noninvasive Cancer Diagnostics Revenue by Players (2020, 2021 & 2022)
5 Global Noninvasive Cancer Diagnostics Market Size by Region
5.1 Global Noninvasive Cancer Diagnostics Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Noninvasive Cancer Diagnostics Market Size by Region (2017-2028)
5.2.1 Global Noninvasive Cancer Diagnostics Market Size by Region: 2017-2022
5.2.2 Global Noninvasive Cancer Diagnostics Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Noninvasive Cancer Diagnostics Market Size YoY Growth 2017-2028
6.1.2 North America Noninvasive Cancer Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Noninvasive Cancer Diagnostics Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Noninvasive Cancer Diagnostics Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Noninvasive Cancer Diagnostics Market Size YoY Growth 2017-2028
6.3.2 Europe Noninvasive Cancer Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Noninvasive Cancer Diagnostics Market Size YoY Growth 2017-2028
6.4.2 Latin America Noninvasive Cancer Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Noninvasive Cancer Diagnostics Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Noninvasive Cancer Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Precision Therapeutics, Inc. (U.S.)
7.1.1 Precision Therapeutics, Inc. (U.S.) Company Details
7.1.2 Precision Therapeutics, Inc. (U.S.) Business Overview
7.1.3 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Introduction
7.1.4 Precision Therapeutics, Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2017-2022)
7.1.5 Precision Therapeutics, Inc. (U.S.) Recent Development
7.2 A&G Pharmaceutical, Inc. (U.S.)
7.2.1 A&G Pharmaceutical, Inc. (U.S.) Company Details
7.2.2 A&G Pharmaceutical, Inc. (U.S.) Business Overview
7.2.3 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Introduction
7.2.4 A&G Pharmaceutical, Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2017-2022)
7.2.5 A&G Pharmaceutical, Inc. (U.S.) Recent Development
7.3 Affymetrix Inc. (U.S.)
7.3.1 Affymetrix Inc. (U.S.) Company Details
7.3.2 Affymetrix Inc. (U.S.) Business Overview
7.3.3 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Introduction
7.3.4 Affymetrix Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2017-2022)
7.3.5 Affymetrix Inc. (U.S.) Recent Development
7.4 AVIVA Biosciences Corporation (U.S.)
7.4.1 AVIVA Biosciences Corporation (U.S.) Company Details
7.4.2 AVIVA Biosciences Corporation (U.S.) Business Overview
7.4.3 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Introduction
7.4.4 AVIVA Biosciences Corporation (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2017-2022)
7.4.5 AVIVA Biosciences Corporation (U.S.) Recent Development
7.5 BIOVIEW Inc. (U.S.)
7.5.1 BIOVIEW Inc. (U.S.) Company Details
7.5.2 BIOVIEW Inc. (U.S.) Business Overview
7.5.3 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Introduction
7.5.4 BIOVIEW Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2017-2022)
7.5.5 BIOVIEW Inc. (U.S.) Recent Development
7.6 Laboratory Corporation of America Holdings (LabCorp) (U.S.)
7.6.1 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Company Details
7.6.2 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Business Overview
7.6.3 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Introduction
7.6.4 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2017-2022)
7.6.5 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Recent Development
7.7 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
7.7.1 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Company Details
7.7.2 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Business Overview
7.7.3 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Introduction
7.7.4 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2017-2022)
7.7.5 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Recent Development
7.8 Digene Corporation (U.S.)
7.8.1 Digene Corporation (U.S.) Company Details
7.8.2 Digene Corporation (U.S.) Business Overview
7.8.3 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Introduction
7.8.4 Digene Corporation (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2017-2022)
7.8.5 Digene Corporation (U.S.) Recent Development
7.9 Gen-Probe Incorporated (U.S.)
7.9.1 Gen-Probe Incorporated (U.S.) Company Details
7.9.2 Gen-Probe Incorporated (U.S.) Business Overview
7.9.3 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Introduction
7.9.4 Gen-Probe Incorporated (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2017-2022)
7.9.5 Gen-Probe Incorporated (U.S.) Recent Development
7.10 IVDiagnostics, Inc. (U.S.)
7.10.1 IVDiagnostics, Inc. (U.S.) Company Details
7.10.2 IVDiagnostics, Inc. (U.S.) Business Overview
7.10.3 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Introduction
7.10.4 IVDiagnostics, Inc. (U.S.) Revenue in Noninvasive Cancer Diagnostics Business (2017-2022)
7.10.5 IVDiagnostics, Inc. (U.S.) Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
